Dr Xiaoli Meng Ph.D.

Research Overview

My main research interests are the use of advanced mass spectrometry-based multiomics techniques to investigate drug metabolism, explore drug-protein interaction/adduct, and discover HLA antigens that could lead to immunological reactions. My team has established a unique platform that integrates state-of the art analytical and immunological tools to address some of the most challenging questions in the field of drug hypersensitivity. We have developed analytical platforms to characterise drug-protein adducts in patients and within different cells including antigen presenting cells (B cells and dendritic cells), Keratinocytes, and hepatocytes. We were the first to show that drug-modified peptides can be presented by specific HLA alleles that can stimulate drug specific T cells. These studies will not only help understand the mechanisms of drug-induced immunotoxicity but also guide design novel therapeutics with improved efficacy and less toxicity. Through collaborating with academic scientists, clinicians, and scientist in the pharmaceutical industry, we are developing novel assays for better diagnosis, prediction, and prevention of drug-induced immunotoxicity. Beyond drug-induced immunotoxicity, my group is also interested in developing novel T-cell based immunotherapies for the treatment of various diseases including cancer and autoimmune diseases.